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Background: C-reactive protein (CRP) exerts prothrombotic effects through dissociating from pentameric CRP (pCRP)
into modified or monomeric CRP (mCRP). However, although the high prevalence of venous thromboembolism (VTE)
in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been identified, it remains
unclear whether the high levels of circulating pCRP potentially contribute to this hypercoagulable state in AAV. ANCA
can induce the generation of neutrophil extracellular traps (NETs). In this study, the NETs-dependent generation of
mCRP from pCRP and the influences of mCRP on the activation of coagulation system and inflammatory response in
AAV were investigated.
Results: NETs were induced after TNF-α primed neutrophils were incubated with ANCA-containing IgG. After
ANCA-induced netting neutrophils were incubated statically with platelet-rich plasma (PRP) containing mCRP
(60 μg/mL), the proportion of platelets expressing CD62p increased significantly, while no increased CD62p
expression of platelets was observed after static incubation with PRP containing pCRP (60 μg/mL). Under flow
conditions, perfusing immobilized ANCA-induced netting neutrophils with pCRP-containing PRP caused platelets
activation and mCRP deposition. The newly generated mCRP induced platelets activation on ANCA-induced netting
neutrophils, enhanced D-dimer formation, and enhanced high mobility group box 1 secretion by platelets.
Conclusions: Under flow conditions, ANCA-induced netting neutrophils can activate platelets and then prompt the
formation of mCRP on activated platelets. Then the newly generated mCRP can further enhance the activation of
platelets, the process of thrombogenesis, and the inflammatory response. So the high level of circulating pCRP is not
only a sensitive marker for judging the disease activity, but also a participant in the pathophysiology of AAV.
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Although anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis (AAV) is a systemic autoinflammatory
disorder that affects small vessels and capillaries predom-
inantly, it had been observed in a number of studies that
there is high prevalence of venous thromboembolism
(VTE) in patients with AAV [1-6]. The levels of circulating
D-dimer, a fibrin degradation product after a blood clot is
degraded by fibrinolysis, are significantly higher in AAV
patients in active stage compared with those in remission
[7]. However, the underlying mechanism of this hyperco-
agulable state in AAV is not yet fully clarified.
The level of circulating C-reactive protein (CRP) is ele-
vated in active phase of AAV, and falls rapidly with remis-
sion of the disease [8]. Interestingly, Ma et al. recently
found that AAV patients with elevated circulating D-
dimer had more severe clinical manifestations and higher
levels of circulating CRP compared to patients with nor-
mal circulating D-dimer. Moreover, correlation analysis
showed that the levels of circulating D-dimer positively
correlated with the levels of circulating CRP [7]. Circulat-
ing CRP belongs to the pentraxin family and contains 5
identical, noncovalently linked subunits (pentameric CRP,
pCRP). Many studies have demonstrated that in cardiovas-
cular disease, the circulating pCRP can dissociate into
modified or monomeric CRP (mCRP) on activated plate-
lets and accelerate thrombogenesis [9-12]. Compared with
cardiovascular disease, the circulating pCRP levels in ac-
tive AAV are generally much higher, but its significance in
VTEs of AAV had been less well studied.
In AAV, ANCA can induce the neutrophil extracellular
traps (NETs) formation after binding neutrophils. NETs
are DNA fibers comprising histones, antimicrobial pro-
teins and tissue factor [13-17]. Since some previous studies
have reported that NETs can provide a scaffold for plate-
lets adhesion and activation, it is reasonable to hypothesize
that circulating pCRP can transform to mCRP on activated
platelets by the aid of ANCA-induced netting neutrophils
and the newly generated mCRP can accelerate thrombo-
genesis in AAV. On the other hand, cumulative evidences
have proved a biologic association between thrombogen-
esis and inflammation. Elevated inflammation is both a
cause and a result of thrombogenesis [18,19]. Thus, it is
also reasonable to speculate that circulating CRP not only
takes part in the process of thrombogenesis in AAV, but
also enhances the subsequent inflammatory response fol-
lowing VTEs. High mobility group box 1 (HMGB-1) is an
intracellular protein that can bind DNA and regulate gene
expression. Besides, it can also function as a kind of pro-
inflammatory mediator when released from cells [20].
Recently published studies have demonstrated that the ac-
tivated platelets can secrete HMGB-1 [21,22].
In this study, we investigated whether ANCA-induced
netting neutrophils could activate platelets and thenprompt the formation of mCRP on activated platelets. We
also investigated whether mCRP could further enhance
the activation of platelets, the formation of D-dimer and
the secretion of HMGB-1 of platelets.
Methods
Patients
Patients’ plasma was obtained from 5 AAV patients with
positive myeloperoxidase (MPO)-ANCA. All 5 patients, di-
agnosed in Tianjin Medical University General Hospital,
fulfilled the 2012 revised International Chapel Hill Consen-
sus Conference Nomenclature of Vasculitides [23]. Plasma
from 2 healthy blood donors was obtained as normal con-
trol. The research was in compliance of the declaration of
Helsinki and approved by the Ethics Committee of Tianjin
Medical University General Hospital. All participants have
provided their written informed consent.
Preparation of materials
High purity (>99%) human pCRP obtained from plasma
was purchased from Sigma-Aldrich (C-4063; St. Louis, MO
USA). pCRP was saved in buffer containing 5 mM calcium
chloride. The level of endotoxin was undetectable as deter-
mined by the Limulus amebocyte lysate assay (ET0200,
Sigma-Aldrich). mCRP was generated by treating pCRP
with 8 M urea in the presence of 10 mM EDTA for 1 hr at
37°C as described previously [24]. IgG fractions from pa-
tients with positive ANCA or healthy donors were purified
by protein G affinity column (GE Healthcare Life Sciences)
and combined together in the following experiments.
Neutrophils were isolated by density centrifugation using
a Histopaque gradient. Briefly, a double gradient was
formed by layering an equal volume of 3 mL Histopaque-
1077 (10771, Sigma-Aldrich) over 3 mL Histopaque-1119
(11191, Sigma-Aldrich). Ethylene diamine tetraacetic acid
(EDTA) anti-coagulated whole blood (6 mL) was carefully
layered onto the upper Histopaque-1077 medium. After
30 min centrifugation at 700 g, neutrophils between two
Histopaque medium were carefully isolated. Cells were
washed by addition of 5 mL of isotonic phosphate buffered
saline (PBS) (0.20 g/L of KCl, 0.20 g/L of KH2PO4, 8 g/L
of NaCl, 1.15 g/L of Na2HPO4) to the tubes. Purity of neu-
trophils was >90% as assessed by flow cytometric analysis.
Platelet-rich plasma (PRP) was obtained from citrate
anti-coagulated whole blood by centrifugation at 20 g for
15 min. The concentration of platelets was adjusted to
100 × 109/L. To remove platelets, PRP was centrifugated
at 3000 g for 15 min and then platelet-free plasma (PFP)
was obtained.
Induction of netting neutrophils by ANCA and isolation of
NETs
Neutrophils (1 × 106/mL) were primed with 5 ng/mL
TNF-α (H8916, Sigma-Aldrich) and incubated with
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patients at 37°C for 4 hr. To collect NETs, the ANCA-
containing supernatant was removed after centrifugation
at 3000 g for 5 min. The precipitate was resuspended
with PBS and was agitated vigorously for 3 min. Then
NETs were collected in the supernatant after centrifuga-
tion at 200 g for 5 min. NETs quantity were assessed by
measuring concentrations of dsDNA with MaestroNano
Micro-Volume Spectrophotometer (MN-913, Maestrogen
Inc., Hsinchu, Taiwan).
Flow cytometry
PRP was incubated with ANCA-induced netting neutro-
phils (1 × 106/mL), pCRP (60 μg/mL), mCRP (60 μg/mL),
0.1 U/μL DNase I (D7076, Beyotime Institute of Biotech-
nology, Haimen, China), netting neutrophils plus pCRP,
netting neutrophils plus mCRP, or netting neutrophils plus
mCRP and DNase I at 37°C for 1 hr respectively. Adenosine
diphosphate (ADP) (A2754, Sigma-Aldrich) at a concentra-
tion of 100 μmol/L was used as a positive control. A fluor-
escein isothiocyanate (FITC) conjugated anti-CD41a mAb
(340929, BD, USA) at a dilution of 1: 10 was used as an
activation-independent marker of platelets. CD62p was
assessed with a phycoerytrin (PE) conjugated anti-CD62P
mAb (561921, BD, USA) at a dilution of 1: 10. After PRP
was incubated with antibodies at 37°C for 30 min, platelets
were centrifuged, washed, resuspended and assessed by
flow cytometry analysis.
Perfusion experiment and colocalization of platelets and
mCRP on ANCA-induced netting neutrophils
Neutrophils (1 × 106/mL) were coated on the Poly-L-
Lysine-coated slides in PBS at 37°C for 1 hr and then were
treated with 5 ng/mL TNF-α (H8916, Sigma-Aldrich) and
ANCA-containing IgG (250 μg/mL) at 37°C for 4 hr. Non-
specific binding sites were blocked in PBS containing 2%
bovine serum albumin (BSA). The slides were placed in
flow chambers (31–010, Glycotech, USA) and perfused
with 10 mL citric acid-anticoagulated PRP or PFP for
10 min at constant shear rates of 1500 s−1. Where indi-
cated, pCRP (60 μg/mL) or mCRP (60 μg/mL) was added
to PRP or PFP before perfusions. After perfusions,
slides were rinsed with PBS and fixed with 3.8%
paraformaldehyde.
Netting neutrophils were stained using 4’,6-diamidino-2-
phenylindole (DAPI) (C1006, Beyotime). Activated plate-
lets were visualized using FITC conjugated anti-CD62p
mAb (550866, BD, USA) at a dilution of 1: 10. mCRP was
identified using specific mouse monoclonal anti-C-reactive
protein (Clone CRP-8) (C1688, Sigma-Aldrich) at a dilu-
tion of 1: 2000 and tetraethyl rhodamine isothiocyanate
(TRITC)-goat anti-mouse antibodies (T5393, Sigma-
Aldrich) at a dilution of 1: 50. The results were visual-
ized with fluorescence microscopy (Leica DMI4000 B)and evaluated with the Image Pro Plus analysis soft-
ware 6.0.
To investigate the effect of mCRP deposited on the acti-
vated platelets during perfusion experiments on the activa-
tion of platelets, ANCA-induced netting neutrophils were
perfused with PRP containing pCRP or mCRP as men-
tioned above. The activated platelets on slides were visual-
ized with FITC conjugated anti-CD62p mAb (550866, BD)
and calculated as activated platelets/visual field.
Western-Blot analysis
Polyacrylamide gel electrophoresis (PAGE) with 1/20 of
normal levels of sodium dodecyl sulfate (SDS) was per-
formed as described previously with minor modifications
[23]. Concentration of stacking gel and separation gel
was 6% and 8% respectively. Prestained molecular mass
markers (SM1811, Thermo Scientific Fermentas) were
used to identify the molecular mass of proteins. pCRP
and mCRP were loaded as controls (1 μg per lane). In
order to investigate whether the pCRP or mCRP was de-
posited after perfusions, substances on the slides after
perfusion experiments were washed off with 200 μL
Hanks solution (containing 1.26 mmol/L Ca2+) and were
loaded (20 μL per lane). In order to investigate whether
NETs could directly dissociate pCRP into mCRP, pCRP
was incubated with isolated NETs at 37°C for 12 hr in
Hanks solution (containing 1.26 mmol/L Ca2+) and then
were loaded (1 μg per lane). Electrophoresis was per-
formed for 60 min. After electrophoresis, the proteins
on gel were transferred onto nitrocellulose membrane at
0.08 mA/cm2 for 70 min and blocked overnight at 4°C
in Tris buffered saline with Tween-20 (TBST) [0.01 mol/L
Tris–HCl, pH 7.2, 0.15 mol/L NaCl, 0.1% (v/v) Tween 20]
containing 1.0% BSA. The membrane was incubated with
Clone CRP-8 (C1688, Sigma-Aldrich) diluted 1:20000 in
TBST containing 1.0% BSA for 1 hr at 37°C. After triple
wash with TBST (10 min each), the membrane was
incubated with horseradish peroxidase-conjugated goat
anti-mouse antibody (136815, Abcam) diluted 1:10000 in
TBST containing 1.0% BSA for 1 hr at 37°C. The result
was revealed on autoradiographic film using ECL Plus
Western Blotting Detection System.
Enzyme-linked immunosorbent assay (ELISA) for
analyzing the binding between mCRP and isolated NETs
Isolated NETs with the adjusted dsDNA concentration of
5 μg/mL were coated on the Poly-L-Lysine-coated plates
in PBS at 37°C for 1 hr. Nonspecific binding sites were
blocked in PBS containing 2% BSA at 37°C for 1 hr. mCRP
at 4.0 μg/mL in PBS was added to the wells in duplicate
and incubated at 37°C for 1 hr. Where indicated, 0.1 U/μL
DNase I (D7076, Beyotime) was added to wells after NETs
were coated on plates, or 0.1 mg/mL polyclonal rabbit
anti-MPO antibodies (N5787, Sigma-Aldrich) were added
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Clone CRP-8 (C1688, Sigma-Aldrich) diluted 1: 1000 in
PBS was added at 37°C for 1 hr followed by incubation at
37°C for 1 hr with anti-mouse IgG (Fab specific)–alkaline
phosphatase antibody produced in goat (A1293, Sigma-
Aldrich) diluted 1:2000 in PBST. The p-nitrophenyl
phosphate (N2770, Sigma-Aldrich) at a concentration of
1 mg/mL was used in substrate buffer [1 M diethanola-
mine and 0.5 mM MgCl2 (pH 9.8)]. Color development
was measured spectrophotometrically at 405 nm (Bio-Rad,
Tokyo, Japan). In each step, the volume was 100 μL and
the plates were washed three times with PBS between
steps. All samples were tested in duplicate.
Measurement of the levels of D-dimer
D-dimer levels of the samples were analyzed on the
VIDAS system (bioMérieux) in our central laboratory. The
single-dose, ready-to-use reagent included a solid-phase
receptacle and a strip. 200 μL of samples were added to
the first well on the strip and then inserts the strip and
corresponding solid-phase receptacle into the analyzer.
The whole assay is carried out at 37°C for 35 min. The D-
dimer concentration was calculated from a calibration
curve specific to the reagent batch stored in the software.
Measurement of the levels of high-mobility group box 1
(HMGB-1)
Plasma levels of HMGB-1 were tested using commer-
cially available ELISA kits (Shino-TEST). The assay was
conducted according to the manufacturer’s instructions.
The specimen (10 μL) was added to immobilized anti-
HMGB-1 antibody on the well together with 100 μL
sample diluent, allowing HMGB-1 to specifically bind to
the antibody. Peroxidase-conjugated secondary antibody
was then added to the sample well. Chromogenic solu-
tion was added to the antigen-antibody complex for
assaying absorbance at 450 nm.
Statistical analysis
Different conditions were performed at least three times
in each subject. Data were shown to be normally distrib-
uted using the Kolmogorov-Smirno test and variables
were expressed as mean ± SD and were evaluated using
independent t-test or one-way ANOVA analysis as ap-
propriate. It was considered significant difference if the
P-value was less than 0.05. Analysis was performed with
SPSS statistical software package (version 19, Chicago,
IL, USA).
Results
Platelets are activated after static incubation with mCRP
or DNase I-pretreated netting neutrophils
When TNF-α primed neutrophils were incubated with
ANCA-containing IgG for 4 hr, DAPI staining showedthat NETs formation could be observed in about 20% of
neutrophils, while normal IgG did not induce NETs for-
mation. Static co-incubation of PRP and ANCA-induced
netting neutrophils did not increase the CD62p expres-
sion of platelets (22.38 ± 0.72% vs. 24.23 ± 1.98% of un-
treated PRP, p = 0.131), while co-incubation of PRP and
ANCA-induced netting neutrophils which were pre-
treated with DNase I increased the CD62p expression of
platelets up to 33.20 ± 3.42% (p = 0.007, compared with
the CD62p expression of platelets after co-incubation of
PRP and ANCA-induced netting neutrophils). These re-
sults suggested that the digested NETs could activate
platelets in static condition. It should be explained that
the digestion of DNA exposed histones which could acti-
vate platelets directly [16]. Co-incubation of PRP, DNase
I-pretreated netting neutrophils and mCRP could in-
crease the CD62p expression of platelets up to 42.48 ±
1.71% (P = 0.009, compared with the CD62p expression
of platelets after co-incubation of PRP and DNase I-
pretreated netting neutrophils). Incubation of PRP with
mCRP alone also increased the CD62p expression of
platelets (30.45 ± 2.02% vs. 24.23 ± 1.98% of untreated
PRP, p = 0.005), while incubation of PRP with pCRP
alone did not (24.32 ± 0.62% vs. 24.23 ± 1.98% of un-
treated PRP, p = 0.930). So mCRP could activate platelets
in static condition. Incubation of PRP with ADP
(100 μmol/L) which was used as a positive control also
increased the CD62p expression of platelets significantly
(Figure 1).
Perfusing ANCA-induced netting neutrophils with pCRP-
containing PRP induces the formation of mCRP on
activated platelets
It has been reported that NETs can offer a scaffold for
platelets binding under flow conditions [16]. In the
current study, when ANCA-induced netting neutrophils
were coated on slides in flow chamber and were perfused
with pCRP-containing PRP at 1500 s−1 for 10 min, acti-
vated platelets (CD62p positive) and deposited mCRP
could be observed on slides. Co-localization analysis
showed that CD62p positive platelets were mainly depos-
ited on the DNA of NETs and mCRP was deposited on ac-
tivated platelets. Static incubation of ANCA-induced
netting neutrophils and pCRP-containing PRP for 10 min
induced no deposition of activated platelets or mCRP, sug-
gesting the activation of platelets relayed on the flow con-
ditions, and the deposition of mCRP relayed on the
activation of platelets. Pretreating the slides with DNase I
digested the DNA and diminished the deposition of acti-
vated platelets and mCRP (Figure 2).
According to the study of Eisenhardt et al. [11], Clone
CRP-8 recognizes both mCRP and pCRP, so Western-
Blot with 1/20 of standard SDS was used to confirm it
was mCRP not pCRP that was deposited on the CD62p
Figure 1 CD62p expression of platelets in static incubation system. A: Flow cytometry analysis of the effect of pCRP and mCRP on the
CD62p expression of platelets incubated statically with ANCA-induced netting neutrophils. ADP at a concentration of 100 μmol/L was used as a
positive control. Results are expressed as the percentages of CD62p positive platelets. Four tubes of each group were analyzed and averaged.
B-G: Representative images of the flow cytometry analysis of the percentages of platelets expressing CD62p. B: PRP were incubated with
ANCA-induced netting neutrophils alone. C: PRP were incubated with ANCA-induced netting neutrophils pretreated with DNase I (0.1 U/μL). D: PRP
were incubated with pCRP (60 μg/mL) alone. E: PRP were incubated with mCRP (60 μg/mL) alone. F: PRP were incubated with ANCA-induced netting
neutrophils and mCRP (60 μg/mL). G: PRP were incubated with ANCA-induced netting neutrophils, mCRP (60 μg/mL) and DNase I (0.1 U/μL).
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were rinsed gently with Hanks solution (containing Ca2+
and Mg2+) then the deposited substances were washed
off vigorously with Hanks solution (containing Ca2+ and
Mg2+) and were subjected to Western-Bolt with 1/20 of
standard SDS. mCRP control (urea/EDTA denatured
pCRP) ran as a single band with a molecular weight of
15 kDa which was close to its expected molecular
weight, while pCRP control ran as a smear without a
single band, suggesting partial dissociation occurred in
Western-Bolt with 1/20 of standard SDS. If there was a
mixture of mCRP and pCRP deposited on activated ple-
telets, both a smear and a single band should be de-
tected in the Western-Bolt with 1/20 of standard SDS.
As shown in Figure 3A, the substances deposited on
slides migrated to a position similar to the mCRP con-
trol, suggesting it was mCRP not pCRP that was depos-
ited on activated platelets after perfusion experiments.
In order to investigate whether NETs could directly
dissociate pCRP into mCRP, pCRP was incubated static-
ally with isolated NETs (without platelets) at 37°C for
12 hr. As shown in Figure 3B, static co-incubation with
NETs did not dissociate pCRP into mCRP.
mCRP does not bind directly on undigested NETs
MPO is an important component of NETs. We have re-
ported that mCRP can bind MPO directly [24]. In orderto further confirm the deposited mCRP in perfusion ex-
periments did not bind NETs directly, immobilized
ANCA-induced netting neutrophils were perfused with
mCRP-containing PFP. As shown in Figure 4A, no de-
position of platelets and mCRP on NETs could be de-
tected after ANCA-induced netting neutrophils were
perfused with mCRP-containing PFP. As shown in
Figure 4B, mCRP did not deposit on the isolated NETs
which were immobilized on plates (0.223 ± 0.035, ex-
pressed as A values at 405 nm) in ELISA analysis. How-
ever, when the immobilized NETs were pretreated with
DNase I, increased binding of mCRP on the digested
NETs was detected (0.617 ± 0.065, expressed as A values
at 405 nm), suggesting some protein(s) contained in
NETs should be the target of the mCRP binding. Poly-
clonal rabbit anti-MPO antibodies inhibited the binding
between mCRP and the digested NETs (0.463 ± 0.049,
expressed as A values at 405 nm). These results further
demonstrated that although NETs contained MPO
which could be bound by mCRP, undigested NETs could
not be bound by mCRP directly. mCRP was only depos-
ited on the activated platelets in perfusion experiments.
mCRP deposited on the activated platelets during
perfusion experiments enhances platelets activation
As mentioned above, although static incubation with
pCRP could not activate platelets, mCRP could generate
Figure 2 Representative images of the depositions of platelets and mCRP on the immobilized ANCA-induced netting neutrophils
(×100). pCRP (60 μg/mL)-containing PRP was used in all groups. DNA was stained as a marker of netting neutrophils using DAPI (blue). Bright
spots were neutrophils without NETs formation while cloud-like structures were NETs. Activated platelets were stained using FITC conjugated
anti-CD62P mAb (green). Deposited mCRP was stained using Clone CRP-8 and TRITC-goat anti-mouse antibodies (red). All experiments were
performed in triplicate. Scale bar: 50 μm.
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sonable to speculate that under flow conditions, pCRP
could enhance platelets activation through dissociating
into mCRP. As shown in Figure 5, the number of acti-
vated platelets per visual field was 10.00 ± 2.23 after per-
fusing netting neutrophils with PRP (containing neither
pCRP nor mCRP), while more activated platelets were
detected after perfusing netting neutrophils with pCRP
(60 μg/mL)-containing PRP (14.80 ± 3.11 activated plate-
lets/visual field). PRP containing 60 μg/mL mCRP was
used as the positive control (19.80 ± 3.19 activated plate-
lets/visual field). These findings were confirmed by pre-
vious studies which reported that mCRP deposited onthe surface of platelets significantly induced platelet ad-
hesion further [25].
mCRP enhances D-dimer formation in perfusion
experiments
Previous studies have reported that immobilized NETs
could provide a scaffold for in vitro thrombogenesis after
perfusion with blood [16]. Since mCRP can enhance the
activation of platelets, it should also be able to enhance
the activation of coagulation and fibrinolysis system
which is initiated by ANCA-induced netting neutrophils
in perfusion experiments. To investigate whether the ex-
istence of mCRP showed a prothrombotic effect in
Figure 3 Western-bolt with 1/20 of standard SDS. A: Western-Blot assay of the CRP deposited on platelets. A typical result from 3 experiments was
shown. pCRP control ran as a smear without a single band (lane 1), while mCRP control ran as a single band with a molecular weight of 15 kDa (lane 2).
The substances deposited on slides ran as a 15 kDa single band without a smear after perfusion experiment with pCRP (60 μg/mL)-containing PRP
(lane 3). A stronger band was detected after perfusion experiment with mCRP (60 μg/mL)-containing PRP (lane 4). The relative intensity of lane 4/lane3
was 2.45 ± 0.63. No smear or single band was detected after perfusion experiment with PRP which did not contain pCRP or mCRP (lane 5). B: Western-
Blot assay of the co-incubation of isolated NETs and pCRP. A typical result from 3 experiments was shown. Lane 1: pCRP control. Lane 2: mCRP control.
Lane 3: a smear without a single band was detected after pCRP was statically incubated with isolated NETs for 12 hr.
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were measured after perfusion. As shown in Figure 6A,
No increased levels of D-dimer could be detected after the
immobilized ANCA-induced netting neutrophils were
perfused with PFP, regardless of whether pCRP or mCRP
was added to the system before perfusions. There was
no increased D-dimer formation after the immobilized
ANCA-induced netting neutrophils were incubated static-
ally with PRP or PFP, regardless of whether pCRP or
mCRP was added to the system. After the immobilizedFigure 4 mCRP does not deposit directly on NETs. A: Representative im
ANCA-induced netting neutrophils were perfused with PRP or PFP (×100).
performed in triplicate. Scale bar: 50 μm. B: Results of ELISA of the binding
of each group were analyzed and averaged.ANCA-induced netting neutrophils were perfused with
PRP, increased levels of plasma D-dimer could be detected
regardless of whether pCRP or mCRP was added to the
system before perfusions, suggesting both coagulant and
fibrinolytic systems were activated after perfusions. The
existences of pCRP (60 μg/mL) or mCRP (60 μg/mL) in
PRP further increased the levels of D-dimer in perfusion
experiments. The levels of D-dimer after the netting neu-
trophils were perfused with mCRP-containing PRP was
higher than that after the netting neutrophils wereages of the immunostaining of activated platelets and mCRP after
Both PRP and PFP contained 60 μg/mL pCRP. All experiments were
between mCRP (60 μg/mL) and immobilized isolated NETs. Four wells
Figure 5 Influence of the mCRP deposited during perfusion experiments on platelets activation. A: Representative images of activated
platelets (CD62p positive) after immobilized ANCA-induced netting neutrophils were perfused with pCRP-containing PRP or mCRP-containing
PRP. The concentration of pCRP or mCRP was 60 μg/mL. Activated platelets were visualized using FITC conjugated anti-CD62P mAb (green).
Scale bar: 50 μm. B: Calculated levels of the deposited CD62p positive platelets after immobilized ANCA-induced netting neutrophils were
perfused with PRP which did not contain pCRP or mCRP, with pCRP-containing PRP or with mCRP-containing PRP. Results were expressed as
activated platelets/visual field. Five visual fields of each group were analyzed.
Figure 6 Effects of mCRP on D-dimer formation and HMGB-1 secretion. A: Effects of mCRP on the D-dimer formation. White columns: D-dimer
levels of plasma after ANCA-induced netting neutrophils were statically incubated with pCRP-containing PRP or mCRP-containing PRP. Gray columns:
D-dimer levels of plasma after ANCA-induced netting neutrophils were perfused with pCRP-containing PFP or mCRP-containing PFP. Black columns:
D-dimer levels of plasma after ANCA-induced netting neutrophils were perfused with pCRP-containing PRP or mCRP-containing PRP. All experiments
were performed in triplicate. B: Effects of mCRP on the HMGB-1 secretion of platelets. White columns: HMGB-1 levels of plasma after isolated NETs were
statically incubated with pCRP-containing PRP or mCRP-containing PRP. Gray columns: HMGB-1 levels of plasma after isolated NETs were perfused with
pCRP-containing PFP or mCRP-containing PFP. Black columns: HMGB-1 levels of plasma after isolated NETs were perfused with pCRP-containing PRP or
mCRP-containing PRP. All experiments were performed in triplicate.
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420.3 ± 30.0 ng/mL, P = 0.008).
mCRP enhances the HMGB-1 secretion of platelets in
perfusion experiments
HMGB-1 can be released by activated platelets. Since
HMGB-1 is able to activate neutrophils in vitro [20], it
has been considered as a potential pathogenic factor
which can accelerate the inflammation of AAV. To in-
vestigate whether mCRP could enhance the HMGB-1 se-
cretion of activated platelets, the levels of HMGB-1 of
plasma were measured after perfusion experiments. In
order to exclude the interference of the HMGB-1 re-
leased by neutrophils, isolated NETs with the adjusted
dsDNA concentration of 5 μg/mL were used to replace
ANCA-induced netting neutrophils at the coating step.
As shown in Figure 6B, No increased levels of HMGB-1
could be detected after isolated NETs were perfused with
PFP, regardless of whether pCRP or mCRP was added to
the system before perfusions. There was no increased
HMGB-1 after the immobilized NETs were incubated
statically with PRP or PFP, regardless of whether pCRP
or mCRP was added to the system.
After the immobilized NETs were perfused with PRP
(containing neither pCRP nor mCRP), the HMGB-1
level of plasma was 4.31 ± 0.49 ng/mL. After the immo-
bilized NETs were perfused with pCRP (60 μg/mL)-con-
taining PRP, the HMGB-1 level of plasma was 5.42 ±
1.05 ng/mL (P = 0.172, compared with the HMGB-1
level of plasma after the immobilized NETs were per-
fused with PRP which contained neither pCRP nor
mCRP). After the immobilized NETs were perfused with
mCRP (60 μg/mL)-containing PRP, the HMGB-1 level of
plasma was 6.05 ± 0.61 ng/mL (P = 0.012, compared with
the HMGB-1 level of plasma after the immobilized NETs
were perfused with PRP which contained neither pCRP
nor mCRP).
Discussion
ANCA can induce the NETs formation of neutrophils and
ANCA-induced netting neutrophils are present in patients
with AAV [14]. As an important component of NETs, his-
tones have been reported to be able to activate platelets
directly and promote thrombin generation [15-17]. In the
current study, undigested netting neutrophils could not
activate platelets, while DNase I-pretreated netting neu-
trophils increased the expression of CD62p of platelets
significantly in static incubation system. This phenomenon
suggests that histones which are masked by the DNA of
intact NETs are necessary for the activation of platelets in
static incubation system. Contrary to the results obtained
in static incubation system, the integrity of DNA is the
prerequisite of the platelets activation in perfusion experi-
ments, because shearing force is one of the key factors forplatelets activation and only the intact DNA can offer a
barrier for retaining platelets from flowing blood [25-27].
Although we could not exclude the possibility that
pCRP also bound activated pletelets with immunofluores-
cence assay, Western-Blot with 1/20 of standard SDS
helped us to distinguish whether the CRP deposited on ac-
tivated platelets was mCRP, pCRP or the mixture of both
mCRP and pCRP. Through this method, we demonstrated
that the deposited CRP was mCRP not pCRP because it
ran as a single band without a smear. Although after per-
fusion experiments, there was still some pCRP which did
not dissociate into mCRP, no smear at higher molecular
weights was detected in Western-Bolt. The reason should
be that slides had been rinsed with Hanks solution (con-
taining Ca2+) and the pCRP which did not bind platelets
was removed before Western-Bolt.
It was noteworthy that static co-incubation of isolated
NETs and pCRP without platelets did not generate mCRP.
So it was not the components of NETs that dissociate
pCRP in perfusion experiments. The existence of activated
platelets should be the prerequisite of the formation of
mCRP. According to previous studies, lysophosphatidyl-
choline exposed on the cell membrane of activated plate-
lets can offer a surface for the dissociation of pCRP [9].
On activation and adhesion, platelets undergo a rapid
change in morphology and composition of membrane
lipids, leading to the exposure of bioactive lipid and the
dissociation of adhered pCRP to mCRP [9].
pCRP and mCRP differ in their biological effects. mCRP
can exert various effects that are distinct from those of
pCRP. Intravenous pCRP administration significantly en-
hanced leukocyte rolling, adhesion, and transmigration via
localized dissociation to mCRP, while inhibiting the dis-
sociation of pCRP diminished these effects [27]. Several
studies have demonstrated the important effect of mCRP
on the activation of coagulation system [10,12]. Similar to
the results of previous studies, we found that the platelets
could be activated by mCRP in static incubation system.
mCRP could even enhance the activation of platelets in-
duced by DNase I-pretreated netting neutrophils in static
incubation system. We also found mCRP deposited on the
activated platelets could enhance the activation of platelets
and the formation of D-dimer in perfusion experiments.
So the activation of platelets in perfusion experiments
with pCRP-containing PRP should be induced by two fac-
tors: shearing force and the deposited mCRP. To the best
of our knowledge, our study is the first to show a causal
role of mCRP on the thrombosis in AAV.
Although the expression of tissue factor in NETs has
been reported by previous studies [28], we did not find
the formation of D-dimer after the static co-incubation
of netting neutrophils and PRP or after the perfusion of
netting neutrophils with PFP. On the other hand, al-
though the static co-incubation of mCRP and PRP could
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dimer. Interestingly, the existence of mCRP could enhance
the formation of D-dimer when the immobilized ANCA-
induced netting neutrophils were perfused with PRP.
Therefore, we think both flow conditions and platelets are
necessary for the activation of coagulation system induced
by ANCA-induced netting neutrophils, and the existence
of mCRP should accelerate this process.
More and more studies demonstrate that inflammation
and thrombosis can influence each other [18,19]. On
one hand, inflammation has been suggested as a risk fac-
tor for VTE, on the other hand, apparent systemic in-
flammatory responses can be found in the acute phase
of deep vein thrombosis [18,19]. HMGB-1 is an intracel-
lular protein and function as a kind of proinflammatory
mediator in AAV when released from cells. The levels of
HMGB-1 in active AAV patients are significantly higher
than those in remission [29-32]. Incubation of neutro-
phils with HMGB-1 significantly increases the NETs for-
mation of neutrophils in vitro [20]. Interestingly, Wang
et al. found that plasma levels of HMGB-1 correlated
with circulating CRP level in AAV [32]. In the current
study, we found that the existence of mCRP enhanced
the HMGB-1 secretion of platelets under flow condi-
tions. This indicates mCRP might be a potential link be-
tween thrombosis and inflammation in AAV.
We did not find direct binding of pCRP or mCRP to
the activated neutrophils in perfusion experiments. This
seems to be in contrast to the current literature [33].
We think there might be some reasonable explanations
for this phenomenon. First, the duration of perfusion ex-
periments (10 min) was not long enough. Second, before
perfusion experiments, neutrophils had been incubated
with ANCA and the Fc receptors on neutrophils, which
were also the potential receptors for pCRP and mCRP,
had been occupied by ANCA. Third, the NETs sur-
rounded the activated neutrophils and prevented the
binding of pCRP or mCRP on the cell surface.
In the current study, we also did not find the direct
binding between mCRP and the undigested NETs, while
NETs pretreated by DNase I could be bound by mCRP.
Although this phenomenon could be explained by the
binding between MPO and mCRP, it was noteworthy that
polyclonal rabbit anti-MPO antibodies could not inhibit
the binding totally (the A 405 nm was decreased by only
26%). This phenomenon means there might be some other
components in NETs which can bind mCRP. Actually,
previous studies indicate that mCRP has lectin-like prop-
erties and can bind galactose-containing residues [34-36].
So one possible explanation might be that mCRP also
binds some substances in NETs which are full of galactose.
This hypothesis needs further investigation.
The current study provides a potential link between
mCRP and VTEs in AAV. Therefore, elevated circulatingpCRP not only is a biomarker of AAV, but also plays an
important role in the pathogenesis of AAV. Although
our experiments are done in vitro, it is reasonable to
speculate that all these processes might also occur
in vivo. First, ANCA has been proved to be an important
NETs inducer and enhanced formation NETs has been
reported in patients with AAV [13]. Immunostaining in
kidney tissue of humans with AAV demonstrated the ex-
istence of NETs [14]. The direct proof of the participa-
tion of NETs in the thrombogenesis in AAV has been
reported. In the study of Nakazawa et al., NETs were iden-
tified in the thrombus in an AAV patient with deep vein
thrombosis. The authors also found that the amount of
NETs in the thrombus was significantly greater in that pa-
tient when compared with other thrombi unrelated to
AAV [37]. Second, NETs have been proved to be able to
induce apoptosis of endothelial cells directly in vitro, so
the NETs induced by ANCA might injure the endothelial
cells and offer a surface for the activation of coagulation
system in AAV [38]. Third, the existence of mCRP in AAV
has been proved by the previous study, which found that
mCRP was observed in the cytoplasm of tubules and inter-
stitium of renal biopsies from nine out of the ten patients
with AAV [39].
There are some limitations of this study. First, no im-
munostaining of mCRP in the thrombus of patients with
AAV was done and our understanding of the patho-
physiology of pCRP dissociation was based on in vitro
findings. Second, although hypercoagulable state is asso-
ciated with the disease activity of AAV, the significance
of the VTEs in AAV still needs further elucidation. Pre-
vious studies indicated the patients who had a VTE
event seemed to be older than patients without VTE,
but no differences about the indexes of disease severity
were found between two groups [5]. It is noteworthy
that all previous studies do not include a prospective
screening protocol for VTEs and investigators count
only clinically apparent VTEs for incidence estimates
[1-5]. So the real incidence of VTEs in AAV and the in-
fluences of VTEs on the disease severity of AAV need to
be investigated in future.
Conclusions
In conclusion, ANCA-induced NETs can activate plate-
lets and then prompt the formation of mCRP on acti-
vated platelets. Then the newly generated mCRP can
further enhance the activation of platelets, the process of
thrombogenesis, and the inflammatory response. So we
think the increased circulating pCRP might be a poten-
tial therapy target in AAV and should be paid more
attention.
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